Costs of biomarker testing in advanced non-small cell lung cancer: a global study comparing next-generation sequencing and single-gene testing

被引：0

作者：

Malapelle, Umberto ^{[1
]}

Chen, Chien-Chin ^{[2
]}

de alava, Enrique ^{[3
,4
]}

Hofman, Paul ^{[5
]}

Kazdal, Daniel ^{[6
,7
]}

Kim, Tae-Jung ^{[8
]}

Lim, Tony Kiat Hon ^{[9
]}

Ryska, Ales ^{[10
,11
]}

Saetta, Angelica A. ^{[12
]}

Schuuring, Ed ^{[13
]}

Troncone, Giancarlo ^{[1
]}

Biscuola, Michele ^{[3
]}

Chen, Yi-Lin ^{[14
]}

Tan, Gek San ^{[9
]}

Marquette, Charles Hugo ^{[15
]}

Michelli, Maria ^{[12
]}

ter Elst, Arja ^{[13
]}

Vosmikova, Hana ^{[10
,11
]}

Kapp, Joshua ^{[16
]}

Gonzalez-McQuire, Sebastian ^{[16
]}

Giannopoulou, Andromachi ^{[16
]}

Franzini, Jean Marie ^{[17
]}

Aramburu, Victoria Lucia Rabsiun ^{[17
]}

Baggi, Anna ^{[17
]}

Stenzinger, Albrecht ^{[6
,7
]}

机构：

[1] Univ Naples Federico II, Dept Publ Hlth, Naples, Italy

[2] Chia Yi Christian Hosp, Ditmanson Med Fdn, Dept Pathol, Chiayi, Taiwan

[3] Univ Seville, Virgen Rocio Univ Hosp, Inst Biomed Sevilla IBiS, CSIC,CIBERONC, Seville, Spain

[4] Univ Seville, Sch Med, Dept Normal & Pathol Cytol & Histol, Seville, Spain

[5] Univ Cote Azur, Lab Clin & Expt Pathol, IHU RespirERA, FHU OncoAge,Biobank 0033 00025, Nice, France

[6] Heidelberg Univ, Ctr Personalized Med ZPM, Heidelberg, Germany

[7] German Ctr Lung Res DZL, Translat Lung Res Ctr Heidelberg TLRC H, Heidelberg, Germany

[8] Catholic Univ Korea, Dept Hosp Pathol, Yeouido St Marys Hosp, Coll Med, Seoul, South Korea

[9] Singapore Gen Hosp, Div Pathol, Singapore, Singapore

[10] Charles Univ Prague, Fac Med, Fingerland Dept Pathol, Hradec Kralove, Czech Republic

[11] Univ Hosp Hradec Kralove, Hradec Kralove, Czech Republic

[12] Natl & Kapodistrian Univ Athens, Sch Med, Dept Pathol 1, Mol Diagnost Unit, Athens, Greece

[13] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands

[14] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pathol, Tainan, Taiwan

[15] Univ Cote Azur, Dept Thorac Oncol, CHU Nice, IHU RespirERA, Nice, France

[16] Amgen Europe, Rotkreuz, Switzerland

[17] BIP Consulting, Life Sci Div, Milan, Italy

来源：

JOURNAL OF PATHOLOGY CLINICAL RESEARCH | 2025年 / 11卷 / 02期

关键词：

cost comparison; next-generation sequencing; NSCLC; precision medicine; predictive biomarker; single-gene testing; CARE;

D O I：

10.1002/2056-4538.70018

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Current European/US guidelines recommend that molecular testing in advanced non-small cell lung cancer (aNSCLC) be performed using next-generation sequencing (NGS). However, the global uptake of NGS is limited, largely owing to reimbursement constraints. We compared real-world costs of NGS and single-gene testing (SGT) in nonsquamous aNSCLC. This observational study was conducted across 10 pathology centers in 10 different countries worldwide. Biomarker data collected via structured questionnaires (1 January-31 December 2021) were used to feed micro-costing analyses for three scenarios ['Starting Point' (SP; 2021-2022), 'Current Practice' (CP; 2023-2024), and 'Future Horizons' (FH; 2025-2028)] in both a real-world model, comprising all biomarkers tested by each center, and a standardized model, comprising the same sets of biomarkers across centers. Testing costs (including retesting) encompassed personnel costs, consumables, equipment, and overheads. Overall, 4,491 patients with aNSCLC were evaluated. Mean per-patient costs decreased for NGS relative to SGT over time, with real-world model costs 18% lower for NGS than for SGT in the SP scenario, and 26% lower for NGS than for SGT in the CP scenario. Mean per-biomarker costs also decreased over time for NGS relative to SGT. In the standardized model, the tipping point for the minimum number of biomarkers required for NGS to result in cost savings (per patient) was 10 and 12 in the SP and CP scenarios, respectively. Retesting had a negligible impact on cost analyses, and results were robust to variation in cost parameters. This study provides robust real-world global evidence for cost savings with NGS-based panels over SGT to evaluate predictive biomarkers in nonsquamous aNSCLC when the number of biomarkers to be tested exceeds 10. Widespread adoption of NGS may enable more efficient use of limited healthcare resources.

引用

页数：14

共 49 条

[1] Cancer Facts & Figures, (2024)
[2] Ganti A.K., Klein A.B., Cotarla I., Et al., Update of incidence, prevalence, survival, and initial treatment in patients with non-small cell lung cancer in the US, JAMA Oncol, 7, pp. 1824-1832, (2021)
[3] Michelotti A., de Scordilli M., Bertoli E., Et al., NSCLC as the paradigm of precision medicine at its finest: the rise of new druggable molecular targets for advanced disease, Int J Mol Sci, 23, (2022)
[4] Sholl L.M., Cooper W.A., Kerr K.M., Et al., IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer, (2023)
[5] de Jager V.D., Timens W., Bayle A., Et al., Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries, Lancet Reg Health Eur, 38, (2024)
[6] Hendriks L.E., Kerr K.M., Menis J., Et al., Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up, Ann Oncol, 34, pp. 339-357, (2023)
[7] Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.5.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. [Accessed 1 May 2024]. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way
[8] Hendriks L.E., Kerr K.M., Menis J., Et al., Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up, Ann Oncol, 34, pp. 358-376, (2023)
[9] Mosele M.F., Westphalen C.B., Stenzinger A., Et al., Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group, Ann Oncol, 35, pp. 588-606, (2024)
[10] Bestvina C.M., Waters D., Morrison L., Et al., Cost of genetic testing, delayed care, and suboptimal treatment associated with polymerase chain reaction versus next-generation sequencing biomarker testing for genomic alterations in metastatic non-small cell lung cancer, J Med Econ, 27, pp. 292-303, (2024)

← 1 2 3 4 5 →